EPIDUO GEL Rx
Generic Name and Formulations:
Adapalene 0.1%, benzoyl peroxide 2.5%; gel.
Galderma Laboratories, Inc.
Indications for EPIDUO GEL:
Treatment of acne vulgaris in patients ≥9 years of age.
Adults and Children:
<9yrs: not established. ≥9yrs: apply thin film to affected areas of face and/or trunk once daily after washing. Use a pea-sized amount for each area of the face (eg, forehead, chin, cheek). Reduce frequency or discontinue if prolonged or severe irritation occurs.
Do not use on cuts, abrasions, eczematous or sunburned skin. Avoid eyes, lips, mucous membranes, sun, UV light. Increased irritation in extreme weather. Pregnancy (Cat.C). Nursing mothers.
Retinoid + antibacterial/keratolytic.
Caution with other topical acne therapy (eg, peeling, desquamating, or abrasive agents). Avoid using concomitant topical irritants and waxing treated areas.
Dry skin, contact dermatitis, skin irritation, eczema; local reactions (eg, erythema, scaling, dryness, burning, stinging), may bleach fabrics or hair.
Adapalene: biliary. Benzoyl peroxide: renal.
Gel—45g (tube or pump); Forte Gel—15g, 30g, 45g, 60g, 70g pump
Clinical Pain Advisor Articles
- Chronic Neuropathic Pain Updated Classification by IASP for ICD-11
- Buprenorphine-Naloxone Found to Be More Cost-Effective Than Extended-Release Naltrexone
- Ultrasound-Guided C2 Coblation May Be Effective for Cervicogenic Headache
- Meta-Analysis of Opioid Treatment for Chronic Noncancer Pain
- Opioids Found to Increase Risk for Community-Acquired Pneumonia, Particularly in HIV
- Reviewing the Use of Buprenorphine in Perioperative Pain Management
- Early Physical Therapy for Musculoskeletal Pain May Reduce Opioid Use
- External Trigeminal Nerve Stimulation May Alleviate Migraine Pain
- IASP Updates Diagnosis Criteria for Chronic Primary Pain for ICD-11
- Galcanezumab Provides Persistent Preventive Effects in Episodic, Chronic Migraine
- Comparable Analgesia With Low-Dose IV Ketamine, Morphine for Acute Pain
- Benzodiazepines, if Prescribed, May Not Affect Methadone Treatment Retention
- When Opioid Prescribing Guidelines Become Rules
- IV Fluid Confers No Significant Treatment Effect on Migraine Pain
- American Headache Society Releases Position Statement on Novel Preventive and Acute Migraine Treatments